Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 1:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: pramlintide Clear all
Completed Phase 2 Interventional Results available

Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin

NCT00819234
View directory record Official record
Conditions
Obesity
Interventions
Placebo, Pramlintide and Metreleptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arkansas • Santa Rosa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 19, 2026, 1:55 PM EDT
Completed Not applicable Interventional

Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus

NCT01839370
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Closed Loop with Pramlintide
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2014 · Synced Sep 19, 2026, 1:55 PM EDT
Not listed Phase 3 Interventional

Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus

NCT01137695
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Pramlintide
Drug
Lead sponsor
Cheryl Rosenfeld, DO
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Denville, New Jersey • Staten Island, New York • Langhorne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2011 · Synced Sep 19, 2026, 1:55 PM EDT
Completed No phase listed Observational Results available

An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

NCT00229658
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
107
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 19, 2026, 1:55 PM EDT
Completed Phase 4 Interventional Results available

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

NCT00690235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
Interventions
Pramlintide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 19, 2026, 1:55 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

NCT00392925
View directory record Official record
Conditions
Overweight, Obesity
Interventions
pramlintide acetate 360 mcg, metreleptin, placebo-pramlintide 600 uL, placebo-metreleptin 1 mL, Pramlintide acetate 180 mcg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
DeLand, Florida • Chicago, Illinois • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 19, 2026, 1:55 PM EDT
Terminated Not applicable Interventional

Glucagon Counterregulation in Type 1 Diabetes

NCT03547427
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Basal insulin alone, Basal pramlintide and reduced basal insulin, CGM, Acetaminophen test, Insulin-induced hypoglycemia, Exercise-induced hypoglycemia
Other
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 19, 2026, 1:55 PM EDT
Withdrawn Phase 4 Interventional

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

NCT00505882
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide, Glargine, Lispro, Aspart
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 19, 2026, 1:55 PM EDT
Completed Phase 2 Interventional

A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

NCT00112021
View directory record Official record
Conditions
Obesity
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
21
States / cities
Chula Vista, California • San Diego, California • Walnut Creek, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 19, 2026, 1:55 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide

NCT00691158
View directory record Official record
Conditions
Obesity
Interventions
Pramlintide (Amylin), Placebo (Normal Saline), 2 Metreleptin, Leptin plus Pramlintide
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Sep 19, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Role of Amylin and Glucagon in T1DM

NCT00206258
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Pramlintide and glucagon
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 19, 2026, 1:55 PM EDT
Completed Phase 4 Interventional Results available

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

NCT00467649
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
pramlintide acetate (Symlin), rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
37
States / cities
Northport, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 19, 2026, 1:55 PM EDT
Active, not recruiting Early Phase 1 Interventional

Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease

NCT03560960
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Pramlintide challenge test
Drug
Lead sponsor
Boston University
Other
Eligibility
60 Years to 90 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 19, 2026, 1:55 PM EDT
Completed Phase 4 Interventional

A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

NCT00502138
View directory record Official record
Conditions
IDDM
Interventions
Continuous Pramlintide infusion
Drug
Lead sponsor
University Diabetes & Endocrine Consultants
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 19, 2026, 1:55 PM EDT
Completed Phase 4 Interventional

The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes

NCT00950677
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Byetta (exenatide), Symlin (pramlintide)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2017 · Synced Sep 19, 2026, 1:55 PM EDT
Completed Phase 2 Interventional

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

NCT00402077
View directory record Official record
Conditions
Overweight, Obesity
Interventions
pramlintide acetate, sibutramine, phentermine, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 19, 2026, 1:55 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus

NCT01165944
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pramlintide
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 19, 2026, 1:55 PM EDT
Completed Phase 2 Interventional

Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide

NCT00044707
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Sep 19, 2026, 1:55 PM EDT